Yestar Health (02393) has announced that it is considering forming a joint venture with New Genetron Holding Limited (Genetron Health) in Singapore, which may expand its operations into Indonesia, Malaysia, and Singapore. According to current plans, the proposed joint venture will register a new entity in Indonesia, focusing on designing, building, and operating clinical molecular diagnostic laboratories centered on precision oncology. When appropriate, it will also establish production facilities for in vitro diagnostic reagents and kits locally. In other words, the proposed joint venture will create advanced medical laboratories in Indonesia that provide sophisticated genetic testing, including cancer screening, to help doctors detect diseases early and tailor treatment plans to patients' needs. The joint venture will emphasize advanced molecular diagnostic services, employing cutting-edge laboratory testing to understand diseases at the molecular level, particularly in the field of precision oncology, which delivers customized cancer care based on each patient's unique genetic mutations and cancer type. Key products will include early cancer screening tests, such as Genetron Health's innovative HCCscreen and HCCscan products based on NGS or qPCR technologies, which have gained global recognition, including Breakthrough Device Designation from the U.S. FDA for the HCCscreen. Other offerings will encompass comprehensive genomic analysis, minimal residual disease (MRD) monitoring, and non-invasive prenatal testing (NIPT). Initially, operations will primarily feature laboratory-developed tests (LDTs) and will gradually expand to local manufacturing and broader insurance coverage, leveraging Genetron Health's technology and regulatory combinations. The joint venture is expected to establish clinical and business partnerships with renowned hospitals and medical institutions in Indonesia for sample collection, product validation, and early clinical applications. It will also set up a joint board of directors and management team for strategic oversight and will be responsible for all necessary regulatory filings with Indonesian authorities, ensuring strict compliance with local health regulations. There are multiple plans to seize opportunities for business expansion into Indonesia and neighboring Southeast Asian markets. The board believes that the proposed joint venture with Genetron Health will enable the group to leverage Genetron’s leading expertise in precision oncology, proprietary NGS technology, patented sample preparation methods, and globally recognized clinical laboratory and regulatory infrastructure. By combining Genetron Health’s innovative product portfolio and research capabilities with the group's existing distribution and manufacturing experience, the joint venture aims to accelerate the rollout and localization of impactful cancer screening, diagnostic, and monitoring solutions in Indonesia and Southeast Asia. Establishing this joint venture will expedite the group's development in the rapidly evolving diagnostics market, diversify revenue sources, and enhance competitive advantage in delivering healthcare services. By entering high-potential markets through collaboration rather than solo initiatives, the group can mitigate regulatory and operational risks while benefiting from regional and international networks to capitalize on the growing demands for healthcare consumption and advanced diagnostic solutions. The board recognizes the increasing demand for quality diagnostics in Indonesia, improvement in insurance coverage, and favorable demographic trends that create substantial growth prospects for the local healthcare sector. Opportunities for NIPT, cancer screening, and precision medicine remain vast. This collaborative partnership is anticipated to reinforce the group’s position in the healthcare technology sector, generating sustainable long-term value for shareholders.